Mesh implantation during abdominal wall reconstruction decreases rates of ventral hernia recurrence and has become the dominant method of repair. The authors provide a comprehensive comparison of surgical outcomes and complications by location of mesh placement following ventral hernia repair with onlay, interposition, retrorectus, or underlay mesh.
A systematic search of the English literature published from 1996 to 2012 in the PubMed, MEDLINE, and Cochrane library databases was conducted to identify patients who underwent abdominal wall reconstruction using either prosthetic or biological mesh for ventral hernia repair. Demographic information was obtained from each study.
Sixty-two relevant articles were included with 5824 patients treated with mesh repair of a ventral hernia between 1996 and 2012. Mesh position included onlay (19.6 percent), underlay (60.7 percent), interposition (6.4 percent), and retrorectus (12.4 percent). Prosthetic mesh was used in 80 percent of repairs and biological mesh in 20 percent. The weighted mean incidences of early events were as follows: wound complications, 19 percent; wound infections, 8 percent; seroma or hematoma formation, 11 percent; and reoperation, 10 percent. The weighted mean incidences of late complications included 8 percent for hernia recurrence and 2 percent for mesh explantation. Recurrence rates were highest for onlay (17 percent) or interposition (17 percent) reinforcement. The infection rate was also highest in the interposition cohort (25 percent). Seroma rates were lowest following a retrorectus repair (4 percent).
Mesh reinforcement of a ventral hernia repair is safe and efficacious, but the location of the reinforcement appears to influence outcomes. Underlay or retrorectus mesh placement is associated with lower recurrence rates.
From the Departments of Plastic Surgery and General Surgery, Georgetown University Hospital.
Received for publication January 25, 2013; accepted May 21, 2013.
Disclosure:Drs. Nahabedian and Bhanot are members of the speakers’ bureau for LifeCell Corporation (Branchburg, N.J.). Dr. Attinger is a consultant for KCI, Novartis, and Smith & Nephew. The other authors have no relevant conflicts of interest or financial disclosures. No funding was used for the preparation of this article.
Parag Bhanot, M.D., Department of Surgery, Georgetown University Hospital, Fourth Floor PHC Building, 3800 Reservoir Road NW, Washington, D.C. 20007 email@example.com